Enb Therapeutics Is Developing Therapies To Break Drug Resistance That Occurs In Over 50Of Cancer Patientsour Lead Productenb 001Is A First In Classselective Small Molecule Endothelin B Receptoretbrinhibitor Shown In Multiple Preclinical Studies To Significantly Reduce Tumor Growth And Prolong Survival In Cancer Animal Modelsenb 001 Is The Key To Unlock The Full Therapeutic Potential Of Immunotherapy By Restoring The Ability Of T Cells To Infiltrate Tumorsinhibiting Metastasis And Prolonging Patient Survivalgranted Orphan Drug Designation By Fda In 2016Enb 001 Has Solid Market Exclusivity And Strong Ipa Low Costtime Efficient Development Program Provides Near Term Poc Within 18 Months From Financinga Companion Diagnostic Will Detect Etbr Pathway Over Expressers Creating Additional Opportunities For Indication Expansion Into Multiple Tumor Types And Broader Participation In The Multi Billion Dollar Immunotherapy Market
